All the news Showing 8 of 78 articles from: Triple therapyGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Interferon-lambda as effective as alpha but with much better safety profile in hepatitis C Michael Carter / 20 April 2012 A new form of pegylated interferon is associated with significantly fewer side-effects than the standard form of the drug, a study conducted in patients with the easier-to-treat hepatitis C genotypes shows. Data from ... Telaprevir and boceprevir boost sustained response rates for HIV/HCV coinfected Liz Highleyman / 07 March 2012 Adding a first-generation hepatitis C virus (HCV) protease inhibitor to pegylated interferon/ribavirin dramatically increases the likelihood of 12-week sustained virological response to hepatitis C treatment among HIV/HCV coinfected people, researchers reported on Tuesday at ... Common side-effects of hepatitis C protease inhibitors: clinical management advice published Michael Carter / 20 January 2012 The addition of the protease inhibitors telaprevir or boceprevir to hepatitis C treatment regimens increases the risk of anaemia, according to a review article published in Liver International. The author also found that ... Hepatitis C drug boceprevir achieves 70% viral suppression rate in HIV co-infected people within 24 weeks Gus Cairns / 22 October 2011 Interim results presented at the Infectious Diseases Society of America (IDSA) conference yesterday show that 70.5% of 98 patients with HIV and hepatitis C who took the hepatitis C protease inhibitor (PI) drug ... Boceprevir response and resistance differs according to HCV genotype 1 subtype Liz Highleyman / 28 July 2011 People with hepatitis C virus (HCV) genotype 1b respond better to boceprevir and are less likely to develop drug resistance than those with genotype 1a, according to study findings reported ... US approval for hepatitis C drug telaprevir Keith Alcorn / 23 May 2011 The US Food and Drug Administration has approved a new hepatitis C drug telaprevir (Incivek), the agency announced today. Telaprevir is a direct-acting antiviral drug (an HCV protease inhibitor), licensed for use in combination ... European approval recommended for hepatitis C drug boceprevir Keith Alcorn / 23 May 2011 The European Medicines Agency has recommended marketing approval for Merck’s hepatitis C protease inhibitor boceprevir (Victrelis), the agency announced on May 20th. Boceprevir is the first direct-acting antiviral agent for hepatitis C to be ... New hepatitis C drugs pose many questions Keith Alcorn / 08 April 2011 Even before new hepatitis C drugs come to market later this year, the vast array of hepatitis C antivirals currently in clinical trials is opening up new horizons for treatment of hepatitis ... ← Prev1...45678Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive